Anti-GD2 antibodies in treatment of high-risk Neuroblastoma: present and perspectives
Previous
Previous
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1).
Next
Next